Finding a cure for Cystic Fibrosis is a team effort, requiring the the expertise, knowledge and dedication of scientific and medical professionals in a diverse range of areas and roles.

Cure4CF is about finding a cure for Cystic Fibrosis. The Foundation aims to achieve this through raising funds to support promising areas of research in Cystic Fibrosis. To date, our focus has been on supporting the work of the Adelaide CF Airway Gene Therapy Research Group, as they develop a gene therapy approach to treat and potentially cure Cystic Fibrosis Airway Disease.

Finding a cure for Cystic Fibrosis is a team effort. Led by Dr David Parsons, PhD, the research team enjoys the commitment and expertise of a diverse range of scientific and medical specialists.

Team Members Include

Team Leader

Associate Professor David Parsons is the leader of the Cystic Fibrosis Stream at the Children’s Research Centre and Chief Medical Scientist in the Department of Respiratory And Sleep Medicine at the Women’s and Children’s Hospital. He is also Head of the Adelaide Cystic Fibrosis Airway Gene Therapy Group at the Robinson Institute, and an Affiliate Senior Lecturer in the Discipline of Paediatrics at the University of Adelaide.

Associate Professor David Parsons has devoted the past 18 years to finding a cure for Cystic Fibrosis (CF) airway disease and has twice-won Service Excellence Awards administered by the Women’s and Children’s Health Network for his innovations in this and related fields, and was recently recognised as a fellow of the ANZSRS. He and his research team have pioneered a ground-breaking gene therapy technique that has been successful in reversing the basic cellular defect that causes CF in mouse models, and that holds promise as a long-lasting treatment for CF lung disease.

He was also responsible for initiating leading-edge research into the surface behaviour of airways in health and disease using non-invasive synchrotron X-ray imaging techniques. By monitoring the ASL and microscopic particles previously considered too small to view in living airways, David hopes to pioneer new and more effective ways of measuring the success of respiratory treatments like gene therapy in CF patients.

David’s development of CF airway gene transfer methods were supported initially by the USA CF Foundation, and have evolved to attract funding from other funding bodies, including the National Health and Medical Research Council in Australia.

Postdoctoral Scientists

Dr Martin Donnelley

Dr Trish Cmielewski

Dr Nigel Farrow

Dr Chantelle McIntyre

Postgraduate Students

Ms Harsha Padmanabhan

Mr Ryan Green

Ms Alexandra McCarron

Administrative Staff

Ms Bernadette Boog


Dr Greg Smith
+61 (0)8 816 17008

Dr Smith is a clinical respiratory specialist and allergist in the Respiratory and Sleep Medicine Department and part of the CF Clinic team at the WCH. He joined the CF Research Team in 2004, and provides practical experience and advice around the clinical development of CF airway gene therapy and technique training (e.g. bronchoscopic vector delivery). This important experimental-clinical interface assists research to relate to CF patient needs, assisting in the design and analysis of the animal model studies. His input is invaluable as we move towards translation of pre-clinical gene therapy protocols into human clinical trials.


University of North Carolina: Prof Richard Boucher
Monash University: Dr Karen Siu, A/Prof Andreas Fouras, Dr Kaye Morgan, A/Prof Anne Chidgey
Melbourne University: A/Prof Ivan Bertoncello
University of Western Australia: A/Prof Yuben Moodley, A/Prof Anthony Kicic
SAHMRI: Dr Tim Kuchel
UniSA: A/Prof Albert Juhasz, Dr Euan Smith, Dr Darren Miller, Dr Ivan Lee